Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug

Dow Jones

May 05

By Rob Curran

Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition.

The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said.

No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure.

Shares of Cytokinetics rose 21% to $80.08 premarket.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

May 05, 2026 08:56 ET (12:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2633943114"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633943114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633943114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633943114","market":"sg","top_or_hot":-1,"title":"Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n</p>\n<p>\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n</p>\n<p>\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n</p>\n<p>\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics Rises After Promising Late-Stage Trial of Heart Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics Rises After Promising Late-Stage Trial of Heart Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-05 20:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CYTK\">Cytokinetics</a> rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n</p>\n<p>\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n</p>\n<p>\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n</p>\n<p>\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2026 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTK","symbol_name":"Cytokinetics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633943114","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633943114","pubTimestamp":1777985760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition.The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said.No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure.Shares of Cytokinetics rose 21% to $80.08 premarket.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYTK":"Cytokinetics","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"心脏药物后期试验后细胞动力学上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1.5,"CYTK":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Cytokinetics rallied after one of the biopharmaceutical company's product candidates showed promise in a late-stage trial for patients with a heart condition. \n\n\n  The South San Francisco, Calif., company's aficamten met primary end-points in a Phase 3 trial for patients with non-obstructive hypertrophic cardiomyopathy. Patients taking the treatment showed statistically significant improvements in exercise capacity and symptom burden, the company said. \n\n\n  No new safety concerns arose during the trial. Left ventricular ejection fraction below 50% occurred in 27 patients taking aficamten, and two patients suffered a serious adverse event of heart failure. \n\n\n  Shares of Cytokinetics rose 21% to $80.08 premarket. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 08:56 ET (12:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}